Merck price target raised to $143 from $142 at Truist

Truist raised the firm’s price target on Merck to $143 from $142 and keeps a Buy rating on the shares after the company reported Q1 revenue and EPS that beat consensus and raised and narrowed FY24 guidance. The company expects continued growth from Keytruda, particularly in early lung cancer, Gardasil, and anticipates a strong Winrevair launch, notes the analyst, who also points out that Merck has three upcoming PDUFA decision dates for V116, Keytruda and MK-1022.